# Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy

> **NCT00363051** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 160 (actual)

## Conditions studied

- Islet Cell Carcinoma
- Neuroendocrine Carcinoma
- Neuroendocrine Tumor
- Pancreatic Neoplasms

## Interventions

- **DRUG:** Everolimus 10 mg
- **DRUG:** Octreotide Depot

## Key facts

- **NCT ID:** NCT00363051
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2008-01
- **Final completion:** 2012-04
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2013-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00363051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00363051, "Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00363051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*